These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 30715373)

  • 1. Antibody Determinants of Influenza Immunity.
    Crowe JE
    J Infect Dis; 2019 Apr; 219(Suppl_1):S21-S29. PubMed ID: 30715373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.
    Eichelberger MC; Monto AS
    J Infect Dis; 2019 Apr; 219(Suppl_1):S75-S80. PubMed ID: 30715357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
    Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.
    Whittle JR; Wheatley AK; Wu L; Lingwood D; Kanekiyo M; Ma SS; Narpala SR; Yassine HM; Frank GM; Yewdell JW; Ledgerwood JE; Wei CJ; McDermott AB; Graham BS; Koup RA; Nabel GJ
    J Virol; 2014 Apr; 88(8):4047-57. PubMed ID: 24501410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.
    Kirkpatrick E; Henry C; McMahon M; Jiang K; Strohmeier S; van Bakel H; Wilson PC; Krammer F
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32907980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins.
    Ross TM
    J Infect Dis; 2019 Apr; 219(Suppl_1):S57-S61. PubMed ID: 30715379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017.
    Catani JPP; Smet A; Ysenbaert T; Vuylsteke M; Bottu G; Mathys J; Botzki A; Cortes-Garcia G; Strugnell T; Gomila R; Hamberger J; Catalan J; Ustyugova IV; Farrell T; Stegalkina S; Ray S; LaRue L; Saelens X; Vogel TU
    Elife; 2024 May; 12():. PubMed ID: 38805550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single cycle influenza virus coated in H7 haemagglutinin generates neutralizing antibody responses to haemagglutinin and neuraminidase glycoproteins and protection from heterotypic challenge.
    Powell TJ; Rijal P; McEwen-Smith RM; Byun H; Hardwick M; Schimanski LM; Huang KA; Daniels RS; Townsend ARM
    J Gen Virol; 2019 Mar; 100(3):431-445. PubMed ID: 30714896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.
    Wang W; Chen Q; Ford-Siltz LA; Katzelnick LC; Parra GI; Song HS; Vassell R; Weiss CD
    Clin Infect Dis; 2019 May; 68(12):2067-2078. PubMed ID: 30256912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
    Ni Y; Guo J; Turner D; Tizard I
    Front Immunol; 2018; 9():1815. PubMed ID: 30140267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.
    Marcelin G; Sandbulte MR; Webby RJ
    Rev Med Virol; 2012 Jul; 22(4):267-79. PubMed ID: 22438243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Molecular Determinants of Antibody Recognition and Antigenic Drift in the H3 Hemagglutinin of Swine Influenza A Virus.
    Abente EJ; Santos J; Lewis NS; Gauger PC; Stratton J; Skepner E; Anderson TK; Rajao DS; Perez DR; Vincent AL
    J Virol; 2016 Sep; 90(18):8266-80. PubMed ID: 27384658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly conserved neutralizing epitope on group 2 influenza A viruses.
    Ekiert DC; Friesen RH; Bhabha G; Kwaks T; Jongeneelen M; Yu W; Ophorst C; Cox F; Korse HJ; Brandenburg B; Vogels R; Brakenhoff JP; Kompier R; Koldijk MH; Cornelissen LA; Poon LL; Peiris M; Koudstaal W; Wilson IA; Goudsmit J
    Science; 2011 Aug; 333(6044):843-50. PubMed ID: 21737702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure.
    Wei CJ; Yassine HM; McTamney PM; Gall JG; Whittle JR; Boyington JC; Nabel GJ
    Sci Transl Med; 2012 Aug; 4(147):147ra114. PubMed ID: 22896678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.